|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.88B 2.66B 2.49B 4.65B 318B 4.75B 31.69B 12.27B 153B 12.47B 12.2B 533B | P/E Ratio 2023 |
-317x | P/E Ratio 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3.02B 2.78B 2.61B 4.87B 333B 4.97B 33.18B 12.85B 160B 13.05B 12.77B 558B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 30/09/25 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 30/07/25 | Amedisys: Q2 Earnings Snapshot | AQ |
| 30/07/25 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 30/07/25 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 24/04/25 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 1 year | 95.55 |  | 101.02 |
| 3 years | 82.15 | | 101.02 |
| 5 years | 69.36 | | 276.21 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 06/10/2017 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% | ||
| 14/08/25 | Issuer sale | General Counsel | 22,199 | 0.0678% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.94B 1.79B 1.68B 3.13B 214B 3.2B 21.34B 8.26B 103B 8.4B 8.21B 359B | 2.35B 2.04B 1.88B 1.76B 3.29B 225B 3.36B 22.41B 8.68B 108B 8.82B 8.63B 377B |
| Net income | -9.75M -8.46M -7.8M -7.31M -13.65M -933M -13.93M -93.01M -36.01M -450M -36.59M -35.8M -1.56B | 43.23M 37.52M 34.58M 32.4M 60.54M 4.14B 61.8M 413M 160M 2B 162M 159M 6.94B |
| Net Debt | 361M 313M 289M 270M 505M 34.54B 516M 3.44B 1.33B 16.65B 1.35B 1.33B 57.9B | 156M 135M 125M 117M 219M 14.94B 223M 1.49B 577M 7.2B 586M 573M 25.04B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
